Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Validation and Dosimetry Study of [18F]-FBA-A20FMDV2 PET Ligand for Alpha(V)beta6 in Healthy Subjects and in the Lungs of Idiopathic Pulmonary Fibrosis (IPF) Subjects (PETAL Study)

NCT02052297 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT02052297
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02052297 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Validation and Dosimetry Study of [18F]-FBA-A20FMDV2 PET Ligand for Alpha(V)beta6 in Healthy Subjects and in the Lungs of Idiopathic Pulmonary Fibrosis (IPF) Subjects (PETAL Study)
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Terminated
Start date
January 24, 2014
Completion date
April 21, 2016
Enrollment
19 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis